Compare Tango Therapeutics Inc. (TNGX) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Tyson Foods, Inc. — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while Tyson Foods, Inc. trades at $54.3 (market cap $18.92B). The key difference: Tyson Foods, Inc. is far larger — about 5× Tango Therapeutics Inc.'s market cap, and Tyson Foods, Inc. pays a 3.79% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Tyson Foods, Inc. for 77 Days on average.
| TNGX | TSN | |
|---|---|---|
Market Cap | $3.75B | $18.92B |
Volume | 9,619,106 | 2,968,585 |
Sector | Health | Consumer Staples |
52-Week High | $32.90 | $68.75 |
52-Week Low | $7.50 | $50.47 |
Typical Hold Time | 0 Days | 77 Days |
Enterprise Value | $2.77B | $26.19B |
Dividend Yield | — | 3.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Tyson Foods (TSN) trades at $54.22, up 1.21% with a bullish technical signal despite recent volatility. The stock shows mixed earnings performance with two beats and one miss in recent quarters, while maintaining a 53% analyst buy rating. Current valuation metrics include a P/E of 33.2 and P/S of 0.34, with revenue growth projected to $55.7B in 2026. Recent corporate actions include consistent dividend payments of $0.51 per share.
Outlook remains cautiously optimistic with a $65.40 consensus price target representing 21% upside potential. Key risks include ongoing beef segment losses, securities investigations, and margin pressure. The company's ability to maintain dividends while addressing operational challenges will be critical for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
